What biomarker testing is recommended for metastatic Ovarian Cancer

Biomarker Testing for Metastatic Ovarian Cancer

When you have metastatic ovarian cancer (cancer that has spread beyond the ovaries), biomarker testing plays an important role in guiding treatment decisions. Let me explain what testing is recommended and why.

PRIMARY MOLECULAR TESTING: BRCA1/2 and Homologous Recombination Status

According to NCCN Guidelines, the most critical testing for metastatic ovarian cancer focuses on:

BRCA1/2 Mutation Testing (Germline and Somatic)

• This is the highest priority because BRCA status directly determines eligibility for PARP inhibitor maintenance therapy (drugs like olaparib)
• BRCA mutations indicate your cancer cells have difficulty repairing DNA damage, making them vulnerable to specific targeted drugs
• Testing should be done on your most recent tumor tissue in a CLIA-approved laboratory

Homologous Recombination Deficiency (HRD) Status

• If you don't have a BRCA mutation, your doctor will assess whether your tumor is "homologous recombination deficient" (HRD) or "homologous recombination proficient" (HRP)
• This tells your oncologist how much benefit you might get from PARP inhibitors even without a BRCA mutation
• HRD status helps predict treatment response

ADDITIONAL TUMOR MOLECULAR TESTING

According to NCCN Guidelines, at the time of recurrence or for persistent disease, comprehensive tumor analysis should include testing for:

• Microsatellite Instability (MSI) - indicates how stable your tumor's DNA is
• Mismatch Repair (MMR) status - shows if DNA repair mechanisms are working properly
• Tumor Mutational Burden (TMB) - measures how many mutations are in your cancer cells
• BRAF mutations - can indicate eligibility for targeted therapies
• NTRK fusions - another potential target for specific drugs

TUMOR MARKER BLOOD TESTS

CA-125

• This is the standard tumor marker for ovarian cancer monitoring
• Elevated levels correlate with disease extent and treatment response
• Useful for tracking how well treatment is working and detecting recurrence
• Should be measured at baseline and during treatment

HE4 (Human Epididymis Protein 4)

• Some evidence suggests HE4 may be useful as a prognostic marker
• May help detect recurrence earlier than CA-125 alone
• Your doctor may test this if your CA-125 isn't elevated

Other Markers (if clinically indicated)

• Depending on your specific cancer type, additional markers like inhibin, AFP (alpha-fetoprotein), beta-hCG, LDH, CEA, or CA19-9 may be measured

TIMING AND LOCATION OF TESTING

NCCN Guidelines emphasize:

• Testing should be performed on the most recent available tumor tissue (not old samples)
• If tissue isn't available, circulating tumor DNA (ctDNA) testing from a blood sample can be used as an alternative
• All molecular testing must be done in a CLIA-approved facility to ensure accuracy

WHY THIS MATTERS FOR YOUR TREATMENT

Understanding your biomarker profile helps your oncologist:

1. Select maintenance therapy - BRCA/HRD status determines if PARP inhibitors are appropriate
2. Identify targeted therapy options - specific mutations may qualify you for precision medicine approaches
3. Predict treatment response - certain biomarkers indicate which chemotherapies may work better
4. Monitor disease progression - tumor markers help track whether treatment is working
5. Find clinical trials - some trials require specific biomarker profiles

QUESTIONS TO ASK YOUR ONCOLOGIST

1. Have I had BRCA1/2 testing, and what were the results?
2. What is my homologous recombination status (HRD vs. HRP)?
3. Have I had comprehensive tumor molecular testing, and if not, why?
4. Which biomarkers will you use to monitor my response to treatment?
5. Based on my biomarker results, what treatment options are available to me?
6. Are there clinical trials I might be eligible for based on my biomarker profile?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.